States expand investigation of opioid makers, distributors

September 19, 2017 by Geoff Mulvihill

Attorneys general from most states are broadening their investigation into the opioid industry as a nationwide overdose crisis continues to claim thousands of lives.

They announced Tuesday that they had served subpoenas requesting information from five companies that make powerful prescription painkillers and demanded information from three distributors. Forty-one attorneys general are involved in various parts of the civil investigation.

The probe into marketing and sales practices seeks to find out whether the industry's own actions worsened the epidemic.

If the industry cooperates, the investigation could lead to a national settlement. Connecticut Attorney George Jepsen said in an interview that there are early indications that drugmakers and distributors will discuss the matter with the states.

"The advantage of the multi-state approach is that it's not simply about providing a paycheck for damages to states," Jepsen said. "It provides the opportunity to address broader policy concerns and industry practices."

Companies that received the requests said in statements that they were already taking steps to stem the opioid crisis. The drugmaker Janssen, for instance, said it's trying to educate prescribers about the drugs, and distributor Cardinal Health said it supports a variety of efforts to fight the epidemic and would work with attorneys general. Another distributor, AmerisourceBergen, said it has prevented tens of thousands of suspicious opioid orders from shipping.

Allergan spokesman Mark Marmur said his company would cooperate with the investigation but noted that its two branded opioids haven't been promoted for years and made up less than 1 percent of opioids prescribed in the U.S. last year.

PhRMA, a trade group representing drugmakers, declined to comment on the investigation but said it is trying to deter and prevent drug abuse.

The group and some of its members met Monday with New Jersey Gov. Chris Christie, a Republican who is the head of President Donald Trump's task force on opioids, and pledged to try to develop technologies to reduce the risk of addiction and abuse.

The Healthcare Distribution Alliance said in a statement that it's not responsible for the volume of opioid prescribing but that it does want to work on solving the public health crisis.

"While distributors play a vital role as logistics companies, to suggest that they are responsible for the volume of opioids prescribed lacks a fundamental understanding of how the supply chain works and is regulated," John Gray, the group's president and CEO, said in a statement. "Distributors have no ability to influence what prescriptions are written."

The other drug companies targeted in the requests for information are Endo and Teva. The attorneys general also asked for more information from Purdue Pharma; an investigation of that company was announced in June. The other distributor involved is McKesson.

Drug overdoses have become a crisis across the country. The U.S. Centers for Disease Control and Prevention found that in 2015, they killed more than 52,000 Americans. Most of the deaths involved prescription opioids such as OxyContin or Vicodin or related illicit drugs such as heroin and fentanyl. People with addictions often switch among the drugs.

"Too often, prescription opioids are the on-ramp to addiction for millions of Americans," New York Attorney General Eric Schneiderman said in a statement. He said he sees the investigation as one piece of a broader effort to crack down on opioid abuse that includes measures such as the state's requirement that doctors check a database of prescriptions for controlled substances—a way to keep patients from getting multiple prescriptions from multiple doctors.

Dozens of local and state governments have already filed, announced or publicly considered lawsuits against drugmakers or distributors.

Lawyers for the city of Everett, Washington, argued this week that their case against Connecticut-based Purdue Pharma, maker of OxyContin, should be allowed to move ahead after the company asked a judge to dismiss the case.

State and local governments have been taking other action as the epidemic has deepened, with steps ranging from increasing access to naloxone, a drug that reverses overdoses, to restricting initial prescriptions.

On Monday, a group of 37 attorneys general called on health insurance companies to offer incentives for other forms of pain treatment including non-opioid drugs and massage, saying that as it stands now, insurers cover opioids more than other approaches to pain treatment.

The industry group America's Health Insurance Plans said in a statement that it's already working on using education, prevention and other means in an effort to eradicate addiction.

Explore further: States ask insurers to prioritize non-opioid pain treatment

Related Stories

States ask insurers to prioritize non-opioid pain treatment

September 18, 2017
Attorneys general representing the majority of states are asking the insurance industry to encourage pain treatment through means other than prescriptions for opioid painkillers.

Ohio sues five drugmakers over role in opioid crisis

May 31, 2017
The US state of Ohio on Wednesday sued five major producers of prescription opioid medications, accusing them of lying about the deadly risks the painkillers—at the center of a nationwide addiction crisis—posed to public ...

South Carolina sues drug manufacturer over opioid crisis

August 15, 2017
South Carolina has become the latest state to accuse a drug manufacturer of exacerbating its opioid drug crisis by using deceptive marketing, with the state's top prosecutor suing the maker of OxyContin.

Opioids commission recommends that Trump declare a national emergency

August 1, 2017
The White House commission on opioid addiction has recommended that President Donald Trump declare a national emergency over the epidemic that each day kills dozens of Americans.

Trump declares opioid crisis a 'national emergency'

August 11, 2017
US President Donald Trump said Thursday that the opioid crisis in the United States constitutes a "national emergency" and pledged to step up efforts to fight the epidemic.

US city sues maker of painkiller OxyContin

January 20, 2017
A small US city on Thursday filed a lawsuit against Purdue Pharma, the maker of the pain reliever OxyContin, accusing the company of helping fuel an opioid crisis that has devastated the town.

Recommended for you

Study: What patients really think about opioid vs non-opioid medications for chronic pain

August 14, 2018
Prescriptions of opioids for chronic pain has increased dramatically since the 1990s in spite of their known harms. Despite a shortage of scientific studies on the long-term effectiveness of opioids such as morphine, oxycodone ...

Doctors nudged by overdose letter prescribe fewer opioids

August 9, 2018
In a novel experiment, doctors got a letter from the medical examiner's office telling them of their patient's fatal overdose. The response: They started prescribing fewer opioids.

Benzodiazepine and related drug prescriptions have increased among young people in Sweden

August 7, 2018
The prevalence rate of prescriptions for benzodiazepines and benzodiazepine-related drugs (BZD)—medications used to treat anxiety, insomnia, epilepsy and other neuropsychiatric conditions—increased by 22% between 2006 ...

Unwise opioids for wisdom teeth: Study shows link to long-term use in teens and young adults

August 7, 2018
Getting wisdom teeth removed may be a rite of passage for many teens and young adults, but the opioid painkiller prescriptions that many of them receive could set them on a path to long-term opioid use, a new study finds.

Behavioral nudges lead to striking drop in prescriptions of potent antipsychotic

August 1, 2018
A study led by Columbia University's Mailman School of Public Health has found that letters targeting high prescribers of Seroquel (quetiapine), an antipsychotic with potentially harmful side effects in the elderly, significantly ...

US opioid use not declined, despite focus on abuse and awareness of risk

August 1, 2018
Use of prescription opioids in the United States has not substantially declined over the last decade, despite increased attention to opioid abuse and awareness of their risks, finds a study published by The BMJ today.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.